Gene:
UGT1A1
UDP glucuronosyltransferase 1 family, polypeptide A1

Available Guidelines

  1. CPIC Guideline for atazanavir and UGT1A1
  2. PRO Guideline for irinotecan and UGT1A1
  3. DPWG Guideline for irinotecan and UGT1A1

last updated 09/18/2015

1. CPIC Guideline for atazanavir and UGT1A1

Summary

The CPIC dosing guideline recommends considering advising individuals who carry two decreased function UGT1A1 alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function UGT1A1 alleles, respectively.

There's more of this guideline. Read more.


last updated 06/03/2015

2. PRO Guideline for irinotecan and UGT1A1

Summary

A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of UGT1A1*28 genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the UGT1A1*28/*28 genotype, and that high-dose irinotecan (>=240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype.

There's more of this guideline. Read more.




Annotated Labels

  1. FDA Label for arformoterol and CYP2D6,UGT1A1
  2. FDA Label for belinostat and UGT1A1
  3. FDA Label for dolutegravir and UGT1A1
  4. FDA Label for indacaterol and UGT1A1
  5. FDA Label for irinotecan and UGT1A1
  6. FDA Label for nilotinib and UGT1A1
  7. FDA Label for pazopanib and UGT1A1
  8. EMA Label for axitinib and CYP2C19,UGT1A1
  9. EMA Label for erlotinib and EGFR,UGT1A1
  10. EMA Label for pazopanib and UGT1A1
  11. EMA Label for regorafenib and KRAS,UGT1A1
  12. PMDA Label for indacaterol and UGT1A1
  13. PMDA Label for irinotecan and UGT1A1
  14. HCSC Label for irinotecan and UGT1A1
  15. HCSC Label for nilotinib and UGT1A1

last updated 05/29/2015

1. FDA Label for arformoterol and CYP2D6,UGT1A1

Informative PGx

Summary

The FDA-approved label for arformoterol (BROVANA) states those with reduced CYP2D6 and/or UGT1A1 activity do not show changes in their systemic exposure to the drug compared to those with normal CYP2D6 and/or UGT1A1 enzymatic activities.

There's more of this label. Read more.


last updated 08/04/2016

2. FDA Label for belinostat and UGT1A1

Actionable PGx

Summary

The FDA-approved drug label for belinostat (Beleodaq) states that the starting dose should be reduced to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities. However, testing or screening for the *28 allele is not mentioned.

There's more of this label. Read more.



last updated 10/25/2013

4. FDA Label for indacaterol and UGT1A1

Informative PGx

Summary

Steady-state AUC and Cmax of indacaterol were 1.2-fold higher in patients with the (TA)7, (TA)7 (*28) genotype than in patients with the (TA)6, (TA)6 genotype, suggesting no relevant effect of UGT1A1 genotype of indacaterol exposure

There's more of this label. Read more.


last updated 06/13/2016

5. FDA Label for irinotecan and UGT1A1

Actionable PGx

Summary

Individuals who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of CAMPTOSAR treatment. A reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele

There's more of this label. Read more.


last updated 03/18/2016

6. FDA Label for nilotinib and UGT1A1

Actionable PGx

Summary

Nilotinib is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 (rs8175347) are at an increased risk of hyperbilirubinemia when taking nilotinib (testing is not required for UGT1A1).

There's more of this label. Read more.


last updated 02/15/2014

7. FDA Label for pazopanib and UGT1A1

Actionable PGx

Summary

The drug label for pazopanib (VOTRIENT) states that patients with the UGT1A1 (TA)7/(TA)7 genotype (UGT1A1*28/*28) have an increased incidence of hyperbilirubinemia when taking pazopanib, as compared to those with the (TA)6/(TA)7 or (TA)6/(TA)6 genotype.

There's more of this label. Read more.


last updated 09/12/2014

8. EMA Label for axitinib and CYP2C19,UGT1A1

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for axitinib contains pharmacogenetic information related to there being no clinically relevant effects of UGT1A1 genotype or CYP2C19 genotype on axitinib pharmacokinetics.

There's more of this label. Read more.


last updated 10/25/2013

9. EMA Label for erlotinib and EGFR,UGT1A1

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) requires testing tumours for EGFR mutations in patients with non-small cell lung cancer prior to treatment with erlotinib and recommends using a well-validated method of testing. The drug should be used with caution in patients with low expression of UGT1A1 or Gilbert's disease (caused by genetic variants in UGT1A1 gene), due to the inhibitory effects of erlotinib on glucuronidation by UGT1A1 (UGT1A1 genetic testing is not required).

There's more of this label. Read more.


last updated 06/05/2014

10. EMA Label for pazopanib and UGT1A1

Actionable PGx

Summary

The EMA European Public Assessment Report (EPAR) for pazopanib (Votrient) states that the drug may cause mild hyperbilirubinemia in patients with Gilbert's syndrome (associated with reduced UGT1A1 activity and in some cases is caused by an underlying UGT1A1*28 variant) because it is an inhibitor of UGT1A1. It also states that pazopanib may have a greater effect on irinotecan active metabolite exposure in patients with the UGT1A1*28 variant.

There's more of this label. Read more.


last updated 06/26/2014

11. EMA Label for regorafenib and KRAS,UGT1A1

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for regorafenib (Stivarga) is indicated in adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for other available therapies, including patients with KRAS mutant tumors, though physicians are recommended to carefully evaluate benefits and risks when prescribing regorafenib in patients with KRAS mutant tumours. It potentially blocks targets multiple protein kinases. It is also an inhibitor of UGT1A1 and therefore hyperbilirubinemia may occur in patients with Gilbert's syndrome (can be caused by genetic variants in the UGT1A1 gene).

There's more of this label. Read more.


last updated 01/26/2015

12. PMDA Label for indacaterol and UGT1A1

Informative PGx

Summary

The PMDA package insert for indacaterol states that individuals who have low UGT1A1 expression have increased steady-state area under the concentration-time curve (AUC) and maximum plasma concentration (Cmax) as compared to UGT1A1 wild-type individuals.

There's more of this label. Read more.


last updated 01/26/2015

13. PMDA Label for irinotecan and UGT1A1

Actionable PGx

Summary

The PMDA package insert for irinotecan states that individuals who are homozygous for the UGT1A1*6 or *28 alleles, or heterozygous with the *6/*28 genotype, are at an increased risk for severe adverse events, particularly neutropenia.

There's more of this label. Read more.


last updated 06/08/2015

14. HCSC Label for irinotecan and UGT1A1

Actionable PGx

Summary

The product monograph for irinotecan (CAMPTOSAR) notes that a reduced irinotecan starting dose should be considered in individuals homozygous for the UGT1A1*28 (rs8175347) allele, due to the risk for hematologic toxicity.

There's more of this label. Read more.


last updated 03/28/2016

15. HCSC Label for nilotinib and UGT1A1

Actionable PGx

Summary

The product monograph for nilotinib (TASIGNA) notes that patients homozygous for the UGT1A1*28 allele (rs8175347; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib. This drug is indicated for patients with Philadelphia chromosome positive (BCR-ABL1 fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug.

There's more of this label. Read more.


Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below. Please follow the link in the "Position" column for more information about a particular variant. Each link in the "Position" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for UGT1A1

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA *1 N/A N/A N/A
No VIP available CA VA *6 N/A N/A N/A
No VIP available No VIP available VA *27 N/A N/A N/A
No VIP available CA VA *28 N/A N/A N/A
No VIP available No VIP available VA *36 N/A N/A N/A
No VIP available CA VA *37 N/A N/A N/A
No VIP available CA VA *60 N/A N/A N/A
No VIP available No VIP available VA *91 N/A N/A N/A
No VIP available CA VA
rs1042640 NC_000002.11:g.234681544G>C, NC_000002.12:g.233772898G>C, NG_002601.2:g.188155G>C, NG_033238.1:g.17626G>C, NM_000463.2:c.*339G>C, NM_001072.3:c.*339G>C, NM_007120.2:c.*339G>C, NM_019075.2:c.*339G>C, NM_019076.4:c.*339G>C, NM_019077.2:c.*339G>C, NM_019078.1:c.*339G>C, NM_019093.2:c.*339G>C, NM_021027.2:c.*339G>C, NM_205862.1:c.*339G>C, XR_241238.1:n.2134G>C, rs17190748, rs35909575, rs61636700
G > C
SNP
No VIP available CA VA
rs10929302 NC_000002.11:g.234665782G>A, NC_000002.12:g.233757136G>A, NG_002601.2:g.172393G>A, NG_033238.1:g.1864G>A, NM_001072.3:c.862-9898G>A, NM_007120.2:c.868-9898G>A, NM_019075.2:c.856-9898G>A, NM_019076.4:c.856-9898G>A, NM_019077.2:c.856-9898G>A, NM_019078.1:c.868-9898G>A, NM_019093.2:c.868-9898G>A, NM_021027.2:c.856-9898G>A, NM_205862.1:c.61-9898G>A, NR_037694.1:n.-1791C>T, NR_037695.1:n.-1791C>T, NR_037696.1:n.-1791C>T, XR_241238.1:n.924-9898G>A, XR_241240.1:n.1023-9898G>A, XR_241241.1:n.942-9898G>A
G > A
SNP
No VIP available CA VA
rs10929303 NC_000002.11:g.234681416T>C, NC_000002.12:g.233772770T>C, NG_002601.2:g.188027T>C, NG_033238.1:g.17498T>C, NM_000463.2:c.*211T>C, NM_001072.3:c.*211T>C, NM_007120.2:c.*211T>C, NM_019075.2:c.*211T>C, NM_019076.4:c.*211T>C, NM_019077.2:c.*211T>C, NM_019078.1:c.*211T>C, NM_019093.2:c.*211T>C, NM_021027.2:c.*211T>C, NM_205862.1:c.*211T>C, XR_241238.1:n.2006T>C, XR_241239.1:n.1969T>C, XR_241240.1:n.2105T>C, XR_241241.1:n.2024T>C, rs35926297, rs59599681
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2003569 NC_000002.11:g.234667937G>A, NC_000002.12:g.233759291G>A, NG_002601.2:g.174548G>A, NG_033238.1:g.4019G>A, NM_000463.2:c.-997G>A, NM_001072.3:c.862-7743G>A, NM_007120.2:c.868-7743G>A, NM_019075.2:c.856-7743G>A, NM_019076.4:c.856-7743G>A, NM_019077.2:c.856-7743G>A, NM_019078.1:c.868-7743G>A, NM_019093.2:c.868-7743G>A, NM_021027.2:c.856-7743G>A, NM_205862.1:c.61-7743G>A, XR_241238.1:n.924-7743G>A, XR_241239.1:n.-975G>A, XR_241240.1:n.1023-7743G>A, XR_241241.1:n.942-7743G>A, rs17286591
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3755319 NC_000002.11:g.234667582A=, NC_000002.11:g.234667582A>C, NC_000002.12:g.233758936A=, NC_000002.12:g.233758936A>C, NG_002601.2:g.174193A=, NG_002601.2:g.174193A>C, NG_033238.1:g.3664A=, NG_033238.1:g.3664A>C, NM_000463.2:c.-1352A=, NM_000463.2:c.-1352A>C, NM_001072.3:c.862-8098A=, NM_001072.3:c.862-8098A>C, NM_007120.2:c.868-8098A=, NM_007120.2:c.868-8098A>C, NM_019075.2:c.856-8098A=, NM_019075.2:c.856-8098A>C, NM_019076.4:c.856-8098A=, NM_019076.4:c.856-8098A>C, NM_019077.2:c.856-8098A=, NM_019077.2:c.856-8098A>C, NM_019078.1:c.868-8098A=, NM_019078.1:c.868-8098A>C, NM_019093.2:c.868-8098A=, NM_019093.2:c.868-8098A>C, NM_021027.2:c.856-8098A=, NM_021027.2:c.856-8098A>C, NM_205862.1:c.61-8098A=, NM_205862.1:c.61-8098A>C, XR_241238.1:n.924-8098A=, XR_241238.1:n.924-8098A>C, XR_241239.1:n.-1330A=, XR_241239.1:n.-1330A>C, XR_241240.1:n.1023-8098A=, XR_241240.1:n.1023-8098A>C, XR_241241.1:n.942-8098A=, XR_241241.1:n.942-8098A>C, rs35208194, rs36208045, rs57256426
A > C
SNP
No VIP available CA VA
rs4124874 NC_000002.11:g.234665659T>G, NC_000002.12:g.233757013T>G, NG_002601.2:g.172270T>G, NG_033238.1:g.1741T>G, NM_001072.3:c.862-10021T>G, NM_007120.2:c.868-10021T>G, NM_019075.2:c.856-10021T>G, NM_019076.4:c.856-10021T>G, NM_019077.2:c.856-10021T>G, NM_019078.1:c.868-10021T>G, NM_019093.2:c.868-10021T>G, NM_021027.2:c.856-10021T>G, NM_205862.1:c.61-10021T>G, NR_037694.1:n.-1668A>C, NR_037695.1:n.-1668A>C, NR_037696.1:n.-1668A>C, XR_241238.1:n.924-10021T>G, XR_241240.1:n.1023-10021T>G, XR_241241.1:n.942-10021T>G, rs57409706
T > G
SNP
rs4148323 NC_000002.11:g.234669144G>A, NC_000002.12:g.233760498G>A, NG_002601.2:g.175755G>A, NG_033238.1:g.5226G>A, NM_000463.2:c.211G>A, NM_001072.3:c.862-6536G>A, NM_007120.2:c.868-6536G>A, NM_019075.2:c.856-6536G>A, NM_019076.4:c.856-6536G>A, NM_019077.2:c.856-6536G>A, NM_019078.1:c.868-6536G>A, NM_019093.2:c.868-6536G>A, NM_021027.2:c.856-6536G>A, NM_205862.1:c.61-6536G>A, NP_000454.1:p.Gly71Arg, XR_241238.1:n.924-6536G>A, XR_241239.1:n.233G>A, XR_241240.1:n.1023-6536G>A, XR_241241.1:n.942-6536G>A, rs113525835, rs34360183, rs58105808, rs58585123
G > A
SNP
G71R
rs8175347
(TA)6 > (TA)5
(TA)6 > (TA)7
(TA)6 > (TA)8
microsatellite
No VIP available CA VA
rs8330 NC_000002.11:g.234681645G>C, NC_000002.12:g.233772999G>C, NG_002601.2:g.188256G>C, NG_033238.1:g.17727G>C, NM_000463.2:c.*440G>C, NM_001072.3:c.*440G>C, NM_007120.2:c.*440G>C, NM_019075.2:c.*440G>C, NM_019076.4:c.*440G>C, NM_019077.2:c.*440G>C, NM_019078.1:c.*440G>C, NM_019093.2:c.*440G>C, NM_021027.2:c.*440G>C, NM_205862.1:c.*440G>C, XR_241238.1:n.2235G>C, rs3182134, rs35609787, rs386496306, rs57500970
G > C
SNP
No VIP available CA VA
rs887829 NC_000002.11:g.234668570C>T, NC_000002.12:g.233759924C>T, NG_002601.2:g.175181C>T, NG_033238.1:g.4652C>T, NM_000463.2:c.-364C>T, NM_001072.3:c.862-7110C>T, NM_007120.2:c.868-7110C>T, NM_019075.2:c.856-7110C>T, NM_019076.4:c.856-7110C>T, NM_019077.2:c.856-7110C>T, NM_019078.1:c.868-7110C>T, NM_019093.2:c.868-7110C>T, NM_021027.2:c.856-7110C>T, NM_205862.1:c.61-7110C>T, XR_241238.1:n.924-7110C>T, XR_241239.1:n.-342C>T, XR_241240.1:n.1023-7110C>T, XR_241241.1:n.942-7110C>T, rs12990609, rs34790730, rs36207722, rs386619532, rs61315639
C > T
SNP
No VIP available No Clinical Annotations available VA
rs887929
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  None
Alternate Symbols:  UGT1A
PharmGKB Accession Id: PA420

Details

Cytogenetic Location: chr2 : q37.1 - q37.1
GP mRNA Boundary: chr2 : 234668919 - 234681945
GP Gene Boundary: chr2 : 234658919 - 234684945
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

The uridine diphosphate glucuronosyltransferase (UGT) enzymes are a superfamily of enzymes responsible for the glucuronidation of target substrates. The transfer of glucuronic acid renders xenobiotics and other endogenous compounds water soluble, allowing for their biliary or renal elimination [Article:18518849]. The UGT family is responsible for the glucuronidation of hundreds of compounds, including hormones, flavonoids and environmental mutagens [Article:18518849]. Most of the members of the UGT family are expressed in the liver, as well as in other types of tissues, such as intestinal, stomach or breast tissue. A few members are expressed only extrahepatically, such as UGT1A7, UGT1A8, UGT1A10 and UGT2A1 [Article:12893990]. Four families exist within the UGT superfamily: UGT1A, UGT2, UGT3 and UGT8 [Article:16141793]. UGT2 is further divided into two subfamilies, UGT2A and UGT2B, both of which are present on chromosome 4 [Article:12893990]. UGT2A enzymes are involved in the glucuronidation of compounds such as phenolic odorants and polycyclic aromatic hydrocarbon metabolites, though limited studies have been done on this subfamily [Article:23086198]; UGT2B proteins are mainly responsible for the metabolism of steroids [Article:11159850]. The roles of UGT3 and UGT8 family members have not been well characterized [Article:16141793]. The UGT1A family is located on chromosome 2q37, and the members of this group glucuronidate a large variety of compounds. Pharmaceutical drugs are also a common substrate of the UGT family [Article:18518849], which makes the enzymes in this group relevant to pharmacogenetic research.

The UGT1A gene locus

The UGT1A gene locus enables the transcription of nine unique enzymes, UGT1A1, and UGT1A3 through UGT1A10 [Articles:8467709, 18518849]. This occurs by exon sharing, in which one of nine unique exon 1 sequences at the 5' end of the gene is combined with the common exons 2-4 and 5a at the 3' end, forming individual UGT1A transcripts [Article:11434514] (Figure 1). Alternatively spliced isoforms of UGT1A exist, and are formed when exon 5b (seen in the common exon region) is used instead of, or in addition to, exon 5a [Article:18004212]. These alternative isoforms are known as isoforms 2 or UGT1As_i2, and are enzymatically inactive [Articles:18004212, 19997083]. Additionally, four UGT1A pseudogenes exist: UGT1A2p, 11p, 12p and 13p [Articles:11434514, 15179404]. These pseudogenes can be seen in Figure 1, along with the location of two principal UGT1A1 pharmacogenetic variants, *28 and *6, both of which are discussed in detail further on within this summary.

Figure 1. A graphic representation of the human UGT1A locus (not drawn to scale). (A) The locus spans approximately 200 kbp and contains multiple alternative first exons, which together constitute exon 1. Each unique first exon has its own promoter site. The individual exons for each isoform are combined with the common exons 2-4 and 5a by splicing out any intervening sequence. Exons 2-4 and 5a are therefore present in every UGT1A isoform. However, alternatively spliced UGT1A isoforms do exist, and are known as isoforms 2 or UGT1As_i2; these are created when exon 5b is used instead of, or in addition to, exon 5a. An example of the formation of UGT1A4 mRNA is also shown. In (A) the promoter for UGT1A4 can be seen upstream of the gene, (B) shows the pre-mRNA formed after transcription, and (C) shows the final UGT1A4 mRNA transcript after splicing. Though splicing occurring for common exons 2-5a has not been shown in this figure, it is important to note the absence of exon 5b in (C); this alternative exon has been spliced out in order to create the classical form of UGT1A4. The figure also shows the location of two important UGT1A1 pharmacogenetic variants, *28 and *6, both of which are discussed in detail further on. Adapted from [Articles:18491077, 19794410].

UGT1A1

UGT1A1 function

One of the transcripts encoded by the UGT1A locus is UGT1A1, which is at the furthest 3' end of the UGT1A exon 1 region. UGT1A1 is expressed hepatically as well as within the colon, intestine and stomach [Articles:10748067, 9765507]. One of the main functions of UGT1A1 lies within the liver, where it is the sole enzyme responsible for the metabolism of bilirubin, the hydrophobic breakdown product of heme catabolism [Articles:8027054, 18518849]. In general, UGT1A enzymes have considerable overlap in substrate specificities [Article:10836148], however no other isozyme can substitute for the bilirubin glucuronidation activity of UGT1A1 [Article:18518849]. Additionally, no effective alternative pathways exist for the detoxification and elimination of bilirubin, excluding that of photoisomeration, a relatively inefficient pathway as compared to UGT1A1 glucuronidation [Article:12891498]. Patients with Crigler-Najjar Type I (CN1) disease (discussed below) act as models for this concept: they are either homozygotes or compound heterozygotes for inactive enzyme variants, and are also incapable of glucuronidating or eliminating bilirubin [Article:15712364].

UGT1A1 variants

Currently, 113 different UGT1A1 variants have been described throughout the gene. These variants can confer reduced or increased activities, as well as inactive or normal enzymatic phenotypes. These individual variants are described as alleles by the UGT nomenclature committee, and denoted by the * symbol followed by a number.

UGT1A1 alleles and their role in disease

Homozygotes or compound heterozygotes for inactive UGT1A1 alleles have a complete absence of bilirubin glucuronidation and removal, leading to a high serum level of unconjugated bilirubin (hyperbilirubinemia), and a serious condition known as Crigler-Najjar Type I (CN1) disease [Article:18518849]. If left untreated, CN1 is invariably fatal [Article:19830808]. The development of hyperbilirubinemia results in kernicterus, or the buildup of bilirubin within brain tissue. This causes irreversible neurological damage, leading to severe disability or death. Intensive phototherapy can keep bilirubin levels in check, but becomes less effective with age, and the only definitive treatment is liver transplantation [Article:12891498].

Crigler-Najjar Type 2 (CN2), also results from mutations within the UGT1A1 gene, but some residual enzymatic activity remains, conferring a milder phenotype [Article:19830808]. This type can be treated successfully with phenobarbital, which induces expression of UGT1A1, allowing for reduction of unconjugated bilirubin to innocuous levels [Articles:4897277, 3306242, 7989595]. Kernicterus may still develop, however, if bilirubin levels are enhanced, such as during sepsis or trauma [Article:19830808].

Gilbert's syndrome represents the least severe of the inherited unconjugated hyperbilirubinemia conditions [Article:11013440], and results from UGT1A1 glucuronidation activity that is approximately 30% of normal [Article:7565971]. Patients with Gilbert's have fluctuating bilirubin levels, which are often within the standard range [Article:7565971]. Illness, stress or fasting can precipitate a rise in bilirubin levels, leading to hyperbilirubinemia, and symptoms such as jaundice or abdominal discomfort. However, these symptoms will typically resolve themselves, and the syndrome is harmless in adults [Article:7565971]. Though the condition is benign in itself, it is an indicator of reduced UGT1A1 activity, and is therefore important to consider in the context of drug toxicity. Gilbert's syndrome can be caused by a variety of genetic changes, but within Caucasian and African American populations it is most commonly attributed to the UGT1A1*28 variant allele (rs8175347) [Article:9653159]. This allele represents seven thymine-adenine (TA) repeats within the promoter region, as opposed to six that characterizes the wild-type allele (UGT1A1*1) [Article:17898154]. These extra repeats impair proper transcription of the gene, resulting in decreased transcriptional activity of the gene by approximately 70% [Articles:7565971, 12181419]. A different allele, UGT1A1*37, has eight TA repeats at this site, and results in reduced promoter activity to levels lower than that of promoters with the UGT1A1*28 allele [Articles:10091406, 9653159]. In contrast, the allele UGT1A1*36 has only five repeats, and is associated with increased promoter activity of the gene and a reduced risk of neonatal hyperbilirubinemia, a common and typically benign condition [Articles:9653159, 10190918]. In Asian populations, the UGT1A1*6 allele is more common [Article:9784835]. This variant results from a glycine to arginine change at position 71 within the coding region (Arg71Gly; 211G>A; rs4148323) [Article:16609363]. Individuals homozygous for this allele have enzymatic activity at 32% of normal, and can present with Gilbert's syndrome [Article:9630669] as well as neonatal hyperbilirubinemia [Article:10353933].

UGT1A1 alleles have also been associated with the development of various cancers. Along with bilirubin and pharmaceuticals, UGT1A1 enzymes have been seen to glucuronidate benzo(α)pyrene-trans-7,8-dihydrodiol, a precursor to the potent carcinogen
benzo(α)pyrene-7,8-dihydrodiol-9,10-epoxide, which is found in charbroiled food, coal tar, and cigarette smoke [Article:11929814]. They have also been noted to glucuronidate estradiol [Article:12386134], as well as 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP), another carcinogen present in cooked meat [Article:15986396]. UGT1A1 therefore exhibits a protective effect against benzo(α)pyrene and PhIP-mediated carcinogenicity, and modulates levels of estradiol within the body [Articles:11929814, 12386134, 15986396]. The *28 allele has been shown to increase the risk of developing colorectal and breast cancer across multiple studies in Chinese and Caucasian populations 15111762, 10706110, 22559977. The *6 allele was seen to increase the risk of colorectal cancer in one study in a Chinese cohort [Article:15929176]. Since these alleles result in reduced UGT1A1 activity, any associations seen are potentially due to increased exposure to carcinogens and estradiol [Article:18518849]; increased levels of the latter are associated with the development of breast cancer [Article:21813404]. However, several studies have shown no associations between the *28 allele and risk of breast cancer [Articles:17949292, 11401924], and one showed a decreased risk of breast cancer in *28 carriers [Article:15318931].

There is also evidence suggesting that the UGT1A1*28 allele may offer protection from cardiovascular disease (CVD). Bilirubin is a known antioxidant, and is thought to be capable of preventing plaque formation leading to atherosclerosis [Article:20693308]. Multiple studies have found a link between low bilirubin concentrations and an increased risk of CVD [Article:20562445], though this association may be affected by confounders such as obesity or cholesterol levels [Articles:20562445, 22416852]. Since the *28 allele impairs transcription of the UGT1A1 gene, it is associated with significantly increased bilirubin concentrations, and therefore could be an important biomarker for predicting those at decreased risk of CVD [Article:21411679]. Additionally, testing for associations between the *28 allele and CVD allows for a Mendelian randomization approach, which helps avoid confounding or reverse causation, limitations present in the studies linking bilirubin levels with CVD [Articles:22416852, 22805420]. A 2006 study utilizing the Framingham Heart Study population followed 1780 individuals for 24 years, and found that those with the *28/*28 genotype had one third the risk for cardiovascular disease as compared to those with the *1/*28 or *1/*1 genotypes [Article:17000907]. However, additional studies and meta-analyses [Articles:20562445, 12816916], including one with over 67,000 participants [Article:22805420], have failed to find a link between the *28 allele or bilirubin levels and risk for cardiovascular disease or myocardial infarction. (Note: PMID 22805420 conducted analyses using the rs6742078 variant, shown to be in strong linkage disequilbrium with rs8175347).

UGT1A1 allele frequencies

UGT1A1*28 occurs with a frequency of 0.26 - 0.31 in Caucasians, and 0.42 - 0.56 in African Americans, and only 0.09 - 0.16 in Asian populations [Articles:10591539, 9653159]. UGT1A1*6 has allele frequencies in Japanese, Korean and Chinese populations of 0.13, 0.23 and 0.23, respectively [Article:9784835]. Both UGT1A1*36 and UGT1A1*37 occur almost exclusively in populations of African origin, with estimated allele frequencies of 0.03 - 0.10 and 0.02 - 0.07, respectively [Articles:9653159, 10591539, 15388579].

UGT1A1 Pharmacogenetics

Both the *28 and *6 alleles have been well studied in regard to pharmaceutical toxicities. In particular, both alleles have shown associations with the development of irinotecan toxicities [Articles:20562211, 17728214, 19390945]. Irinotecan is a topoisomerase I inhibitor, and is primarily used to treat colorectal cancer, though it is also used to treat solid tumors within other organs [Article:19852077]. As a pro-drug, irinotecan is converted by carboxylesterases to SN-38, a metabolite which has 100-fold higher anti-tumor activity than its parent compound [Article:1651156]. UGT1A1 is the predominant isoform responsible for the glucuronidation of this toxic metabolite, enabling its eventual excretion. However, in vitro studies show that UGT1A7 and UGT1A9 are also involved in SN-38 glucuronidation [Article:12181437]. Irinotecan has a very narrow therapeutic range, and treatment can lead to a variety of side effects, mainly neutropenia and diarrhea, which can be severe enough to reduce dosage or discontinue the drug [Article:18349289]. Indeed, approximately 7% patients who undergo irinotecan treatment and present with severe neutropenia and fever will die from these complications [Article:18466101]. Several studies have also shown that genotyping for the *28 allele before irinotecan treatment for colorectal cancer is cost-effective [Articles:18466101, 19517472], suggesting that testing for this allele may have a place in clinical practice.

Besides irinotecan, UGT1A1 is also responsible for the glucuronidation of drugs such as raloxifene [Article:12019197] and etoposide [Article:12969965], and some associations have been reported between the *28 allele and pharmacokinetic and pharmacodynamic parameters for these drugs [Articles:19371317, 12969965]. Additionally, the development of hyperbilirubinemia during treatment with inhibitors of UGT1A1, such as atazanavir and tranilast, has also been linked to the presence of the *28 allele [Articles:14647407, 17058217].

It has been suggested that including variants from other UGT1A isoforms may lead to stronger associations with drug side effects and pharmacokinetic measures. UGT1A7 exhibits a five-fold higher specific activity for the SN-38 metabolite than UGT1A1 [Articles:10381366, 12181437], and the inclusion of UGT1A7 alleles into association studies with irinotecan toxicity have shown persuasive results: the combination of UGT1A1*28 with UGT1A7*2 and UGT1A7 -57T/G alleles was superior for prediction of neutropenia and dose reduction, as compared to the UGT1A7 or UGT1A1*28 alleles alone. Indeed, UGT1A1*28 allele by itself showed no association with neutropenia or dose reduction in this particular study [Article:18349289]. The UGT1A7 alleles analyzed were associated with a reduction in either glucuronidation activity or transcription activity, providing a mechanistic explanation for the increased risk of toxicity seen [Article:18349289]. A later study by Cecchin et al. found that in multivariate analyses, UGT1A7*3 was the only significant predictor of hematologic toxicity in the first cycle of treatment with FOLFIRI (fluorouracil, leucovorin and irinotecan); UGT1A1*28 was not a predictor of toxicity [Article:19364970]. Another study by Lévesque et al. in patients taking FOLFIRI found in multivariate analyses that UGT1A7*4 (rs11692021) and UGT1A6*5 (rs2070959) were both significant predictors of neutropenia, while UGT1A1*28 was not [Article:23386248]. UGT1A7*4 is associated with a reduction in glucuronidation activity [Articles:12181437, 11037804] which may explain its association with increased risk for neutropenia. UGT1A6 has been shown to glucuronidate SN-38 [Articles:12181437, 10381366], though no information is currently available on how the *5 allele may affect the enzyme. The study also found a dosage effect when considering multiple alleles: assessing UGT1A7*4 and UGT1A6*5 together as a haplotype gave an odds ratio of 2.18 for the development of neutropenia; including the UGT1A9 -688A/C variant allele in the haplotype increased the odds ratio to 5.28. This result suggests that considering multiple UGT1A variants may improve risk prediction for neutropenia [Article:23386248]. In patients taking atazanavir, Lankish et al. found that the combination of the UGT1A1*28, UGT1A7 -57G and UGT1A7*2, and UGT1A3 -66C variants was associated with increased risk of jaundice and hyperbilirubinemia [Article:17058217]. Approximately 20% of atazanavir-treated subjects were homozygous for this haplotype, compared to 40% of atazanavir-treated subjects who presented with grade 3 or 4 hyperbilirubinemia a statistically significant difference. In subjects with exclusively grade 4 hyperbilirubinemia, 100% were homozygous for the haplotype [Article:17058217]. However, it remains uncertain how variants in UGT1A isoforms that are not directly involved in bilirubin metabolism lead to a propensity for atazanavir-induced hyperbiliriubinemia [Article:17058217]. The alleles present in this study were not in linkage disequilibrium (LD) [Article:17058217], but variants within the UGT1A gene cluster often do show high levels of linkage. This suggests the need for more haplotype-based studies, which can determine interactions among UGT1A variants, and potentially provide better predictions of drug toxicities [Article:19364970].

Citation PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenetics and genomics. 2014. Barbarino Julia M, Haidar Cyrine E, Klein Teri E, Altman Russ B. PubMed
History

Submitted by Eden V. Haverfield (PAAR) (January 6, 2006)

Updated by Julia Barbarino (February 21, 2013)

Key Publications
  1. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. The Journal of pharmacology and experimental therapeutics. 2013. Lévesque Eric, Bélanger Anne-Sophie, Harvey Mario, Couture Félix, Jonker Derek, Innocenti Federico, Cecchin Erica, Toffoli Giuseppe, Guillemette Chantal. PubMed
  2. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. Journal of internal medicine. 2013. Stender S, Frikke-Schmidt R, Nordestgaard B G, Grande P, Tybjaerg-Hansen A. PubMed
  3. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010. Hu Zhe-Yi, Yu Qi, Pei Qi, Guo Cheng. PubMed
  4. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. European journal of cancer (Oxford, England : 1990). 2010. Hu Zhe-Yi, Yu Qi, Zhao Yuan-Sheng. PubMed
  5. Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Human mutation. 2010. Sneitz Nina, Bakker Conny T, de Knegt Robert J, Halley Dicky J J, Finel Moshe, Bosma Piter J. PubMed
  6. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. Cecchin Erika, Innocenti Federico, D'Andrea Mario, Corona Giuseppe, De Mattia Elena, Biason Paola, Buonadonna Angela, Toffoli Giuseppe. PubMed
  7. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. International journal of clinical oncology / Japan Society of Clinical Oncology. 2009. Onoue Masahide, Terada Tomohiro, Kobayashi Masahiko, Katsura Toshiya, Matsumoto Shigemi, Yanagihara Kazuhiro, Nishimura Takafumi, Kanai Masashi, Teramukai Satoshi, Shimizu Akira, Fukushima Masanori, Inui Ken-ichi. PubMed
  8. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics. 2008. Strassburg Christian P. PubMed
  9. Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenetics and genomics. 2007. Girard Hugo, Lévesque Eric, Bellemare Judith, Journault Kim, Caillier Bertrand, Guillemette Chantal. PubMed
  10. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. Journal of the National Cancer Institute. 2007. Hoskins Janelle M, Goldberg Richard M, Qu Pingping, Ibrahim Joseph G, McLeod Howard L. PubMed
  11. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology (Baltimore, Md.). 2006. Lankisch Tim O, Moebius Ulrike, Wehmeier Michael, Behrens Georg, Manns Michael P, Schmidt Reinhold E, Strassburg Christian P. PubMed
  12. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006. Lin Jing-Ping, O'Donnell Christopher J, Schwaiger Johannes P, Cupples L Adrienne, Lingenhel Arno, Hunt Steven C, Yang Song, Kronenberg Florian. PubMed
  13. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and genomics. 2006. Boyd Mark A, Srasuebkul Preeyaporn, Ruxrungtham Kiat, Mackenzie Peter I, Uchaipichat Verawan, Stek Michael, Lange Joep M A, Phanuphak Praphan, Cooper David A, Udomuksorn Wandee, Miners John O. PubMed
  14. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. The Journal of infectious diseases. 2005. Rotger Margalida, Taffe Patrick, Bleiber Gabriela, Gunthard Huldrych F, Furrer Hansjakob, Vernazza Pietro, Drechsler Henning, Bernasconi Enos, Rickenbach Martin, Telenti Amalio, Swiss HIV Cohort Study. PubMed
  15. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Human mutation. 2000. Kadakol A, Ghosh S S, Sappal B S, Sharma G, Chowdhury J R, Chowdhury N R. PubMed
  16. Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. The Journal of pediatrics. 1999. Monaghan G, McLellan A, McGeehan A, Li Volti S, Mollica F, Salemi I, Din Z, Cassidy A, Hume R, Burchell B. PubMed
  17. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. The New England journal of medicine. 1995. Bosma P J, Chowdhury J R, Bakker C, Gantla S, de Boer A, Oostra B A, Lindhout D, Tytgat G N, Jansen P L, Oude Elferink R P. PubMed
Variant Summaries rs4148323, rs8175347
Drugs
Drug Substrate (3)
Drug Inhibitor (3)
Chemical (1)
bilirubin7,8
Diseases
Pathways

Haplotype Overview

UGT1A1 haplotypes are sourced from the UGT Alleles Nomenclature page . Please note: the UGT1A1 Nomenclature page has not been updated since 2009 so some information may be out of date.

Notes on the UGT Alleles Nomenclature page:

Please refer to the UGT1A1 VIP Summary for an explanation of the different UGT1A isoforms, and the composition of the UGT1A locus.

  • For each UGT1A isoform, the UGT Alleles Nomenclature page provides a table of the haplotypes and a list of the SNPs within that gene. If available, associated rsIDs are provided in the SNPs list.

  • Any nucleotide changes or nucleotide positions listed in the haplotype tables or SNPs lists refer to genomic DNA.

  • The list of SNPs consists of nucleotide changes ranging from the promoter region of each UGT1A isoform to the intervening sequence between that isoform and the next one (i.e the 5' to 3' direction down the UGT1A locus). For example, the list of SNPs for UGT1A7 begins with SNPs in the promoter region of that isoform and concludes with SNPs within the intervening sequence between UGT1A7 and UGT1A6.

  • Therefore, when looking at the UGT Alleles Nomenclature page for all rs numbers sorted by nucleotide position, note that the SNPs in the promoter region for UGT1A8 are at the beginning of the list, and the SNPs within the common exon region (exons 2-5) are at the end.

Source: PharmGKB

Haplotypes for UGT1A1 (UGT Alleles Nomenclature page)

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Acetaminophen Pathway (therapeutic doses), Pharmacokinetics
    Stylized diagram showing acetaminophen metabolism and transport in the liver.
  1. Acetaminophen Pathway (toxic doses), Pharmacokinetics
    Stylized diagram showing acetaminophen metabolism at higher acetaminophen doses (toxic doses) in the liver
  1. Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Codeine and Morphine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in metabolism of codeine and morphine.
  1. Efavirenz Pathway, Pharmacokinetics/Pharmacodynamics
    Schematic representation of efavirenz metabolism and mechanism of action against HIV.
  1. Erlotinib Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the transportation and metabolism of Erlotinib.
  1. Estrogen Metabolism Pathway
    Estrogen metabolism in the liver.
  1. Etoposide Pathway, Pharmacokinetics/Pharmacodynamics
    Etoposide cellular disposition and effects.
  1. Fluvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Irinotecan Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes which may be involved in the irinotecan pathway.
  1. Irinotecan Pathway, Pharmacokinetics
    Model human liver cell showing blood, bile and intestinal compartments, indicating tissue specific involvement of genes in the irinotecan pathway.
  1. Losartan Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of losartan.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Statin Pathway - Generalized, Pharmacokinetics
    Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

Curated Information ?

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
4-methylumbelliferone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abacavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABT-751
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acenocoumarol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
acetaminophen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acetanilide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alemtuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alfentanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
almotriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amantadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amitriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amprenavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
anastrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
apomorphine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
arformoterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aripiprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
arsenic trioxide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
asparaginase
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aspirin
atazanavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atomoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
atorvastatin
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
axitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
azathioprine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aztreonam
No Dosing Guideline available DL CA VA No VIP available No VIP available
belinostat
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
benztropine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
bevacizumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
bilirubin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
biperiden
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
boceprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bromfenac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bromocriptine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
buprenorphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bupropion
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
busulfan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabergoline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
caffeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
capecitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carbamazepine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
carboplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carisoprodol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carmustine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
carvedilol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cefixime
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
celecoxib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cerivastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cetuximab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cevimeline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chloramphenicol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chloroquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorpromazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cholestyramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cimetidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ciprofloxacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
cisplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
citalopram
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clarithromycin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clobazam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clomipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clopidogrel
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
clozapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
codeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
conjugated estrogens
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
crizotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyclophosphamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyclosporine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyproheptadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cytarabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dapsone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
darunavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dasatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
daunorubicin
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
deferasirox
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
desipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
dexamethasone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dextromethorphan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diclofenac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
didanosine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dienestrol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diltiazem
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diphenhydramine
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
dolutegravir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
donepezil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dopamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
doxepin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
doxorubicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
efavirenz
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eletriptan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eltrombopag
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
elvitegravir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
emtricitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
entacapone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
epirubicin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available PW
erlotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
erythromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
esomeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
estradiol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
estrone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ethambutol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethinyl estradiol
etoposide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
exemestane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ezetimibe
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fenofibrate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flavopiridol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flecainide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
floxuridine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flucloxacillin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flunarizine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flunitrazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluorouracil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flurbiprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
fluvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluvoxamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
frovatriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fulvestrant
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
furosemide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
galantamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gefitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemcitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemfibrozil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemtuzumab ozogamicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
gepirone hydrochloride
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
glibenclamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
grapefruit juice
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
haloperidol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydralazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ibuprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
iloperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
imatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
imipramine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indacaterol
indinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
interferon alfa-2a, recombinant
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
interferon alpha-2b
irinotecan
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
isoniazid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
itraconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ketoconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ketoprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
labetalol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lamivudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lamotrigine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lansoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lapatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lenalidomide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
letrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
leucovorin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levamisole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levodopa
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levothyroxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lisuride
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lopinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lorazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
losartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
lovastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
maraviroc
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
meperidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mephenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mercaptopurine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mesalazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methadone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methotrexate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methyl-CCNU
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metoclopramide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
metoprolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
miconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
midazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
modafinil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
morphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mycophenolate mofetil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nalidixic acid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naltrexone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naphthol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naproxen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naratriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nefazodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nelfinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nevirapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nicotine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nifedipine
No Dosing Guideline available DL CA VA No VIP available No VIP available
nilotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nitrofurantoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nortriptyline
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
olanzapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
omeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
oxaliplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxcarbazepine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxycodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
paclitaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
panitumumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pantoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
paroxetine
No Dosing Guideline available DL CA VA No VIP available No VIP available
pazopanib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
peginterferon alfa-2b
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pentoxifylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pergolide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
perphenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pertuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenacetin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenazopyridine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenobarbital
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenprocoumon
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pimozide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pitavastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pramipexole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prasugrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pravastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prednisone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
primaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
probenecid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
procainamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prochlorperazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propafenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propofol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propranolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
protriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
pyrazinamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinacrine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rabeprazole
raloxifene
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
raltegravir
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
raltitrexed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ramipril
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rasagiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rasburicase
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
regorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
retigabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ribavirin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
rifampin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
risperidone
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ritonavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rituximab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ropinirole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
s 1 (combination)
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
saquinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
selegiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sertraline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
simvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sirolimus
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
SN-38
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
sorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
st. john's wort
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
stavudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfacetamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfadiazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfamethoxazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfanilamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfapyridine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfasalazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfisoxazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sunitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tacrine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tacrolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tegafur
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telaprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telmisartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
temazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
temozolomide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
temsirolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tenofovir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terbinafine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
testosterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tetrabenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
theophylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioguanine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioridazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ticagrelor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
timolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tiotropium
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
tipifarnib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tipranavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolbutamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolcapone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolterodine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
toremifene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tramadol
tranilast
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trastuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tretinoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trifluoperazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trihexyphenidyl
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trimethoprim
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trimipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
troglitazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trovafloxacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
valproic acid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vemurafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
venlafaxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
verapamil
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
viekira pak
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vincristine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vitamin c
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
voriconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vorinostat
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
warfarin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zalcitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
zidovudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zolmitriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zuclopenthixol

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Acidosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Acquired Immunodeficiency Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adenocarcinoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Agranulocytosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alcoholism
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Anemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anemia, Hemolytic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anemia, Hemolytic, Congenital Nonspherocytic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anemia, Sickle Cell
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Angina Pectoris
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmias, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Rheumatoid
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Asthenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Asthma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial Fibrillation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Attention Deficit Disorder with Hyperactivity
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
beta-Thalassemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
biliary tract neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Brain Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cancer or viral infections
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Carcinoma, Hepatocellular
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cholelithiasis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Colonic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Crigler-Najjar Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crohn Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystic Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Death
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Dehydration
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Depression
Diarrhea
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interaction with drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dyslipidaemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Endometrial Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epidermal Necrolysis, Toxic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophagitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophogeal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exanthema
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Fatigue
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Favism
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Fever
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Stromal Tumors
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genital Neoplasms, Female
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gilbert's syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gingival Hyperplasia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Head and Neck Neoplasms
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Heart Diseases
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hepatitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hepatitis C
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HIV
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hodgkin Disease
Hyperbilirubinemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperbilirubinemia, Hereditary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypereosinophilic Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperlipoproteinemia Type II
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Infection
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammatory Bowel Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Jaundice
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Jaundice, Neonatal
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Leukemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Lymphocytic, Chronic, B-Cell
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Nonlymphocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Promyelocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lipodystrophy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Liver Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lung Neoplasms
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lymphoma, Large B-Cell, Diffuse
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lymphoma, Non-Hodgkin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Melanoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metabolic syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Migraine without Aura
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
mucositis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myelodysplastic Syndromes
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Myocardial Ischemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Myoclonus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myopathy, Central Core
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Nausea
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasm Metastasis
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
nephrolithiasis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nephrotoxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neuroblastoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neurotoxicity Syndromes
Neutropenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ocular Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Organ Transplantation
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Osteoporosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Ovarian Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
overall survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pancreatic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Parkinson Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peripheral Vascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pregnancy
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
progression-free survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prostatic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Disease, Chronic Obstructive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rhabdomyolysis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sarcoma, Kaposi
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sjogren's Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stevens-Johnson Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stomach Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Thalassemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thrombocytopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thromboembolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thyroid Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Toxic liver disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
treatment failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
treatment interruptions
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Trismus
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Tuberculosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tuberculosis, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor Lysis Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Uremia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary Incontinence
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Vomiting

Publications related to UGT1A1: 301

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics. 2016. Bins Sander, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. European journal of clinical pharmacology. 2016. Song Ivy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Deferasirox AUC efficacy cutoff and role of pharmacogenetics. European journal of clinical pharmacology. 2016. Allegra S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients. Clinical pharmacokinetics. 2016. Mbatchi Litaty Céphanoée, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum. Asia-Pacific journal of clinical oncology. 2016. Takano Masashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT). Annals of surgical oncology. 2016. Phelip Jean Marc, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2016. Tsai Mao-Song, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug metabolism and pharmacokinetics. 2015. Atasilp Chalirmporn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. Journal of clinical pharmacology. 2015. Peer Cody J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Uncovering drug-responsive regulatory elements. Pharmacogenomics. 2015. Luizon Marcelo R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In Vitro Kinetic Characterization of Axitinib Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Zientek Michael A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. Journal of human genetics. 2015. Jittikoon Jiraphun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clinical pharmacology and therapeutics. 2015. Gammal Roseann S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis. European journal of clinical pharmacology. 2015. Marano M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open forum infectious diseases. 2015. Vardhanabhuti Saran, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics and toxicities of belinostat administered by 48 h continuous infusion in patients with cancer. Journal of clinical pharmacology. 2015. Goey Andrew K L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. World journal of virology. 2015. Aceti Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolism and Disposition of Prescription Opioids: A Review. Forensic science review. 2015. DePriest A Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. Journal of acquired immune deficiency syndromes (1999). 2015. Avihingsanon Anchalee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: Efavirenz pathway, pharmacokinetics. Pharmacogenetics and genomics. 2015. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?. European journal of haematology. 2015. Mattioli Francesca, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics. 2015. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. British journal of clinical pharmacology. 2015. Falvella Felicia Stefania, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug design, development and therapy. 2015. Yang Chen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer. Genetics and molecular research : GMR. 2015. Xu Q, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study. Molecular diagnosis & therapy. 2014. de Oliveira Almeida Vanessa Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A GWAS Study on Liver Function Test Using eMERGE Network Participants. PloS one. 2015. Namjou Bahram, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy. PloS one. 2015. Lin Kuan-Yin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A Phase I Study of UGT1A1 * 28/ * 6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI. Oncology. 2014. Kim Kyu-Pyo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in European and African American smokers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014. Wassenaar Catherine A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness. The pharmacogenomics journal. 2014. Cusato J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor. Pharmacogenetics and genomics. 2014. Mosteller Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. The Journal of antimicrobial chemotherapy. 2014. Nishijima Takeshi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan. Annals of hematology. 2014. Yamasaki Satoshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer. British journal of clinical pharmacology. 2014. Santoro Ana B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014. Innocenti Federico, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An atlas of genetic influences on human blood metabolites. Nature genetics. 2014. Shin So-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014. Brown Andrew Mk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014. Mizzi Clint, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer. Pharmacogenomics. 2014. Liu Xiang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic Factors Affecting Gene Transcription and Catalytic Activity of UDP-Glucuronosyltransferases in Human Liver. Human molecular genetics. 2014. Liu Wanqing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer chemotherapy and pharmacology. 2014. Han Fei-fei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers. Pharmacogenomics. 2014. Wang Huijuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. The Journal of antimicrobial chemotherapy. 2014. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. The pharmacogenomics journal. 2014. Dias M M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer chemotherapy and pharmacology. 2014. Cheng Lei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenetics and genomics. 2014. Barbarino Julia M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica; the fate of foreign compounds in biological systems. 2014. Chiou William J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2014. Chen Yi-Jing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece. International journal of STD & AIDS. 2014. Panagopoulos P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and genomics. 2014. Johnson Daniel H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. Journal of clinical pharmacology. 2014. Suenaga Mitsukuni, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2014. Chen Shuguang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Correction: Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. PloS one. 2014. Wang Ling-Zhi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting. Translational research : the journal of laboratory and clinical medicine. 2014. Lu Chien-Yu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clinical Observations on Associations Between the UGT1A1 Genotype and Severe Toxicity of Irinotecan. Asian Pacific journal of cancer prevention : APJCP. 2014. Lu Yan-Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia. Drug metabolism and pharmacokinetics. 2014. Abumiya Maiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Investigational new drugs. 2013. Goetz Matthew P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. OncoTargets and therapy. 2014. Li Minmin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring the distribution of genetic markers of pharmacogenomics relevance in brazilian and mexican populations. PloS one. 2014. Bonifaz-Peña Vania, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013. Motzer R J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin. Journal of clinical pharmacology. 2013. Lozano Roberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pregnancy and pharmacogenomics in the context of drug metabolism and response. Pharmacogenomics. 2013. Helldén Anders, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. AIDS research and human retroviruses. 2013. Eley Timothy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. British journal of cancer. 2013. Kim S Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharmaceutical research. 2013. McGill Mitchell R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Molecular pharmaceutics. 2013. Chang Jae H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer prevention research (Philadelphia, Pa.). 2013. Sun Dongxiao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Human psychopharmacology. 2013. Cabaleiro Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenetics and genomics. 2013. Innocenti Federico, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TokyoGreen derivatives as specific and practical fluorescent probes for UDP-glucuronosyltransferase (UGT) 1A1. Chemical communications (Cambridge, England). 2013. Terai Takuya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects. European journal of clinical pharmacology. 2013. Chan Sze Wa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert opinion on drug metabolism & toxicology. 2013. Agúndez José A G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. International journal of clinical oncology. 2013. Shibata Takashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics. 2013. Spraggs Colin F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review. The Annals of pharmacotherapy. 2013. Culley Celia L, et al. PubMed
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. The Journal of pharmacology and experimental therapeutics. 2013. Lévesque Eric, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anti-cancer drugs. 2013. Tsuchiya Norihiko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. The pharmacogenomics journal. 2013. Liu X, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. The Journal of infectious diseases. 2013. Ribaudo Heather J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. Journal of internal medicine. 2013. Stender S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antiviral therapy. 2013. Schackman Bruce R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acetaminophen administration in a patient with Gilbert's syndrome. Pediatrics international : official journal of the Japan Pediatric Society. 2012. Nakagawa Taku, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. PloS one. 2013. Wang Ling-Zhi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American journal of human genetics. 2012. Asselbergs Folkert W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics. 2012. Olagunju Adeniyi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil. AIDS research and human retroviruses. 2012. Turatti Lisiane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. The Journal of antimicrobial chemotherapy. 2012. Ferraris Laurenzia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms. Pharmacogenetics and genomics. 2012. Erickson-Ridout Kathryn K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological reviews. 2012. Michaud Veronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: phenytoin pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics. 2012. Dias Mafalda M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. European journal of clinical pharmacology. 2012. Brennan Meghan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012. Peer Cody J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes. Clinical pharmacology and therapeutics. 2012. Spraggs C F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Therapeutic drug monitoring. 2012. Siccardi Marco, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Severe atazanavir-associated hyperbilirubinemia revealing Canton G6PD deficiency in an Asian HIV-infected patient. AIDS (London, England). 2012. Javelle Emilie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. BMC cardiovascular disorders. 2012. McArdle Patrick F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. Molecules (Basel, Switzerland). 2012. Ji Hye Young, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. British journal of cancer. 2011. Thomas F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study. Cancer biology & therapy. 2011. Di Martino Maria Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy. AIDS research and human retroviruses. 2011. Morello Judit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. Journal of clinical pharmacology. 2011. Brainard Diana M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica; the fate of foreign compounds in biological systems. 2011. Court Michael H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. British journal of cancer. 2011. Marcuello E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions. Clinical pharmacology and therapeutics. 2011. Kacevska M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Interactions Between the Immunosuppressant Tacrolimus and the Cholesterol Absorption Inhibitor Ezetimibe in Healthy Volunteers. Clinical pharmacology and therapeutics. 2011. Oswald S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011. Keisner Sidney V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms. Journal of acquired immune deficiency syndromes (1999). 2011. Cicconi Paola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomics and drug response. The New England journal of medicine. 2011. Wang Liewei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011. Tsunoda A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Databases in the area of pharmacogenetics. Human mutation. 2011. Sim Sarah C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The pharmacogenomics journal. 2011. Glimelius B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic Tailoring of Irinotecan-based First-line Chemotherapy in Metastatic Colorectal Cancer: Results of a Pilot Study. Anticancer research. 2011. Freyer Gilles, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. The Journal of infectious diseases. 2011. Lubomirov Rubin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. The Journal of pathology. 2011. Lee Soo-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic contribution to drug response. Cancer journal (Sudbury, Mass.). 2011. Watson Roshawn G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug metabolism and drug interactions. 2011. Cousins Darren, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Therapeutic drug monitoring. 2010. Cattaneo Dario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrobial agents and chemotherapy. 2010. Neely Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. The Journal of molecular diagnostics : JMD. 2010. Pratt Victoria M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines. The pharmacogenomics journal. 2010. Bellemare J, et al. PubMed
Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010. Hu Zhe-Yi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. The American journal of cardiology. 2010. Baudhuin Linnea M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010. Park Wan Beom, et al. PubMed
Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. European journal of cancer (Oxford, England : 1990). 2010. Hu Zhe-Yi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. European journal of cancer (Oxford, England : 1990). 2010. Liu Yong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. McLeod Howard L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clinical pharmacology and therapeutics. 2010. Oswald S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Boige Valérie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. British journal of cancer. 2010. Xu C-F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future oncology (London, England). 2010. Ramírez Jacqueline, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. The pharmacogenomics journal. 2010. Han Ji-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. British journal of cancer. 2010. Zarate R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics. 2010. Fujiwara Yutaka, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?. Drug metabolism reviews. 2010. Strassburg Christian P. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Toffoli Giuseppe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antiretrovirals. Antiviral research. 2010. Tozzi Valerio. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Individualizing dosing of irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010. Ratain Mark J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clinical pharmacology and therapeutics. 2010. Riedmaier S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug metabolism and disposition: the biological fate of chemicals. 2010. Liu Yong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Human mutation. 2010. Sneitz Nina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer chemotherapy and pharmacology. 2009. Meza-Junco Judith, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Transactions of the American Clinical and Climatological Association. 2010. Goldberg Richard M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics. 2009. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. The Journal of antimicrobial chemotherapy. 2009. Anderson Peter L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer. 2009. Gold Heather Taffet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms in the TATA box and upstream phenobarbital-responsive enhancer module of the UGT1A1 promoter have combined effects on UDP-glucuronosyltransferase 1A1 transcription mediated by constitutive androstane receptor, pregnane X receptor, or glucocorticoid receptor in human liver. Drug metabolism and disposition: the biological fate of chemicals. 2009. Li Ye, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug metabolism and disposition: the biological fate of chemicals. 2009. Tolson Antonia H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. Gastrointestinal cancer research : GCR. 2009. Yalçin Suayib. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Addressing the challenges of the clinical application of pharmacogenetic testing. Clinical pharmacology and therapeutics. 2009. Ikediobi O N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinically available pharmacogenomics tests. Clinical pharmacology and therapeutics. 2009. Flockhart D A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clinical pharmacology and therapeutics. 2009. Wenning L A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and biomarkers in colorectal cancer. The pharmacogenomics journal. 2009. Strimpakos A S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADME pharmacogenetics: current practices and future outlook. Expert opinion on drug metabolism & toxicology. 2009. Grossman Iris. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. Cecchin Erika, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics. 2009. Ferraldeschi Roberta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009. Ribrag Vincent, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. British journal of clinical pharmacology. 2009. Trontelj Jurij, et al. PubMed
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. International journal of clinical oncology / Japan Society of Clinical Oncology. 2009. Onoue Masahide, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenetics and genomics. 2009. Lin Rong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Data-driven methods to discover molecular determinants of serious adverse drug events. Clinical pharmacology and therapeutics. 2009. Chiang A P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert opinion on drug metabolism & toxicology. 2009. Phan Viet Hong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. Wagner Lars M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clinical pharmacology and therapeutics. 2009. Yamamoto N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2009. Han Ji-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and pharmacogenomics of anticancer agents. CA: a cancer journal for clinicians. 2009. Huang R Stephanie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal). Molecular diagnosis & therapy. 2009. Pacheco Paula R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology. 2009. Takano Masashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. Seminars in colon & rectal surgery. 2008. Sanoff Hanna K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS (London, England). 2008. Rodríguez-Nóvoa Sonia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. British journal of cancer. 2008. Rouits E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer. 2008. Deeken John F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochemical pharmacology. 2008. Alonen Anna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic pathway analysis of irinotecan. Clinical pharmacology and therapeutics. 2008. Rosner G L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008. Madadi Parvaz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variations in the UDP-glucuronosyltransferase 1A1 gene for the development of unconjugated hyperbilirubinemia in Taiwanese. Pharmacogenomics. 2008. Huang Yang-Yang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. International journal of cancer. Journal international du cancer. 2008. Nordgard Silje H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics. 2008. Funke Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. The pharmacogenomics journal. 2008. Ruzzo A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Archives of toxicology. 2008. Strassburg Christian P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochemical pharmacology. 2008. Kerdpin Oranun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. British journal of cancer. 2008. Kweekel D M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics. 2008. Strassburg Christian P. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008. Liu Chun-Yu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: from bench to byte. Clinical pharmacology and therapeutics. 2008. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antiretroviral agents. Current opinion in HIV and AIDS. 2008. Owen Andrew, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics. 2008. Obradovic Marko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clinical pharmacology and therapeutics. 2008. Corona G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug metabolism and disposition: the biological fate of chemicals. 2008. Ohno Shuji, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008. Lankisch Tim O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008. Cappellini M D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genomic "roadmap" to "better" drugs. Drug metabolism reviews. 2008. Liao Guochun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of mycophenolate mofetil: a promising different approach to tailoring immunosuppression?. Journal of nephrology. 2008. Betonico G N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenetics and genomics. 2007. Girard Hugo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenetics and genomics. 2007. Udomuksorn Wandee, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2007. Singer J B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In silico and in vitro pharmacogenetic analysis in mice. Proceedings of the National Academy of Sciences of the United States of America. 2007. Guo Yingying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. The pharmacogenomics journal. 2007. Zhang A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer science. 2007. Jada Srinivasa Rao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions. Drug metabolism and disposition: the biological fate of chemicals. 2007. Nakajima Miki, et al. PubMed
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. Journal of the National Cancer Institute. 2007. Hoskins Janelle M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. Côté Jean-François, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Stewart Clinton F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007. Kishi Shinji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of green tea compounds on irinotecan metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2007. Mirkov Snezana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS (London, England). 2007. Rodríguez-Nóvoa Sonia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clinical pharmacology and therapeutics. 2007. de Jong F A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. Journal of clinical pharmacology. 2007. Ramchandani Roshni P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006. Innocenti Federico, et al. PubMed
Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology (Baltimore, Md.). 2006. Lankisch Tim O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006. Pillot Giancarlo A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006. Lin Jing-Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. Journal of the National Cancer Institute. 2006. Rebbeck Timothy R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. The oncologist. 2006. de Jong Floris A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Human mutation. 2006. Thomas Sushma S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Toffoli Giuseppe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Molecular pharmacology. 2006. Duret Cedric, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cancer and leukemia group B gastrointestinal cancer committee. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Goldberg Richard M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism: clinical and experimental. 2006. Borlak Jürgen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression of drug pathway proteins is independent of tumour type. The Journal of pathology. 2006. Zhang W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Chemical research in toxicology. 2006. Mutlib Abdul E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Han Ji-Youn, et al. PubMed
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and genomics. 2006. Boyd Mark A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer. 2006. Massacesi Cristian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Gagnon Jean-François, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression of UDP-glucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney. Drug metabolism and disposition: the biological fate of chemicals. 2006. Richardson Terrilyn A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenetics and genomics. 2006. Ramírez Jacqueline, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques. 2006. Takekuma Yoh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacogenetics of HIV therapy. The pharmacogenomics journal. 2006. Rodríguez-Nóvoa S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug metabolism and disposition: the biological fate of chemicals. 2005. Zhang Donglu, et al. PubMed
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. The Journal of infectious diseases. 2005. Rotger Margalida, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Yong Wei Peng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alternate pathways of thyroid hormone metabolism. Thyroid : official journal of the American Thyroid Association. 2005. Wu Sing-Yung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2005. Kuehl Gwendolyn E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005. Rocha Jose Claudio C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population. Drug metabolism and disposition: the biological fate of chemicals. 2005. Koyano Satoru, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. Journal of clinical pathology. 2005. Steiner M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenetics and genomics. 2005. Innocenti Federico, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A1 variation and gallstone formation in sickle cell disease. Blood. 2005. Haverfield Eden V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clinical pharmacokinetics. 2005. Kosoglou Teddy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. International journal of cancer. Journal international du cancer. 2005. Cheng Ting-Chih, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. British journal of cancer. 2004. Marcuello E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. Rouits Elisabeth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Investigational new drugs. 2004. Sparreboom Alex, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clinical pharmacology and therapeutics. 2004. Sai Kimie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. Innocenti Federico, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Irinotecan pharmacogenetics: is it time to intervene?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. McLeod Howard L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. International journal of clinical pharmacology and therapeutics. 2004. Rauchschwalbe S K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood. 2004. Kishi Shinji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nature reviews. Cancer. 2003. Ulrich Cornelia M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. The pharmacogenomics journal. 2004. Danoff T M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of a pharmacogenetic effect by linkage disequilibrium mapping. The pharmacogenomics journal. 2004. Xu C-F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug metabolism and disposition: the biological fate of chemicals. 2003. Watanabe Yuichiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2002. Nakajima Miki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002. Innocenti Federico, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2002. Nakajima Miki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Molecular pharmacology. 2002. Gagné Jean-François, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular pharmacology. 2002. Maglich Jodi M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochemical and biophysical research communications. 2002. Sugatani Junko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. The Journal of pharmacology and experimental therapeutics. 2001. Court M H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. The pharmacogenomics journal. 2002. Iyer L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica; the fate of foreign compounds in biological systems. 2001. Hanioka N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available